Complement Literature

2016 2015 2014 2013 2012 2011
2010 2009 2008 2007 2005



Abou-El-Hassan H, Zaraket H. Viral-derived complement inhibitors: current status and potential role in immunomodulation. Exp Biol Med (Maywood). 2016. pii: 1535370216675772. [Epub ahead of print]. PMID:27798122

Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol. 2016;17:7. PMID:26754737

Alawieh A, Tomlinson S. Injury site-specific targeting of complement inhibitors for treating stroke. Immunol Rev. 2016;274:270-280. PMID:27782326

Angioi A, Fervenza FC, Sethi S, et al. Diagnosis of complement alternative pathway disorders. Kidney Int. 2016;89:278-88. PMID:26806831

Antwi-Baffour S, Kyeremeh R, Adjei JK, Aryeh C, Kpentey G. The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights. 2016;7:6. PMID:26935316

Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol. 2016 Nov 15. [Epub ahead of print]. PMID:27848226

Audemard-Verger A, Descloux E, Ponard D et al. Infections Revealing Complement Deficiency in Adults: A French Nationwide Study Enrolling 41 Patients. Medicine (Baltimore). 2016;95(19):e3548. PMID:27175654

Bao L, Cunningham PN, Quigg RJ. Complement in Lupus Nephritis: New Perspectives.
Kidney Dis (Basel). 2015;1:91-9. PMID:27536669

Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci. 2016;352:177-90. PMID:27524217

Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290-306. PMID:27782320

Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. J Biol Chem. 2016;291:8214-30. PMID:26903516

Blatt AZ, Pathan S, Ferreira VP. Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev. 2016;274:172-190. PMID:27782331

Brennan FH, Lee JD, Ruitenberg MJ, Woodruff TM. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin Immunol. 2016;28:292-308. PMID:27049459

Chen C, Lv Y, Shi Q et al. Low activity of complement in the cerebrospinal fluid of the patients with various prion diseases. Infect Dis Poverty .2016 ;5:35. PMID:27138196

Corvillo F, Bravo García-Morato M, Nozal P et al. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol. 2016 ;184:118-25. PMID:26660535

Daha MR, van Kooten C. Role of complement in IgA nephropathy. J Nephrol. 2016 ;29:1-4. PMID:26567162

de Borst MH. The Complement System in Hemodialysis Patients: Getting to the Heart of the Matter. Nephron. 2016;132:1-4. PMID:26745820

Dellepiane RM, Dell'Era L, Pavesi P et al. Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis. Orphanet  J Rare Dis. 2016;11:64. PMID:27183977

Delpech PO, Thuillier R, SaintYves T et al. Inhibition of complement improves graft outcome in a pig model of kidney autotransplantation. J Transl Med. 2016;23;14(1):277. PMID:27663514

Dickinson BL. Unraveling the immunopathogenesis of glomerular disease. Clin Immunol. 2016;169:89-97. PMID:27373970

Dobó J, Pál G, Cervenak L, Gál P. The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond.
Immunol Rev. 2016;274:98-111. PMID:27782318

Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016;12:563-78. PMID:27452363

Ekdahl KN, Teramura Y, Hamad OA et al. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev. 2016;274:245-269. PMID:27782319

Ekdahl KN, Huang S, Nilsson B, Teramura Y. Complement inhibition in biomaterial- and biosurface-induced thromboinflammation. Semin Immunol. 2016;28:268-77. PMID:27211838

Elvington M, Liszewski MK, Atkinson JP. Evolution of the complement system: from defense of the single cell to guardian of the intravascular space. Immunol Rev. 2016;274:9-15. PMID:27782327

Emmens RW, Wouters D, Zeerleder S, van Ham SM, Niessen HW, Krijnen PA. On the value of therapeutic interventions targeting the complement system in acute myocardial infarction.
Transl Res. 2016 pii: S1931-5244(16)30267-5. PMID:27810412

Epp Boschmann S, Goeldner I, Tuon FF, Schiel W, Aoyama F, de Messias-Reason IJ. Mannose-binding lectin polymorphisms and rheumatoid arthritis: A short review and meta-analysis. Mol Immunol. 2016;69:77-85. PMID:26608926

Erdei A, Sándor N, Mácsik-Valent B, Lukácsi S, Kremlitzka M, Bajtay Z. The versatile functions of complement C3-derived ligands. Immunol Rev. 2016;274:127-140. PMID:27782338

Ermert D1, Blom AM2. C4b-binding protein: The good, the bad and the deadly. Novel functions of an old friend. Immunol Lett. 2016;169:82-92. PMID:26658464

Fakhouri F, Fila M, Provôt F et al. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol. 2016. pii: CJN.06440616. PMID:27799617

Farkas P, Csuka D, Mikes B et al. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology. 2016. pii: S0171-2985(16)30422-3. PMID:27771173

Farrar CA, Tran D, Li K et al. Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.J Clin Invest. 2016;126:1911-25. PMID:27088797

Ferreira VP, Fazito Vale V, Pangburn MK et al. SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis. Sci Rep. 2016;6:19300. PMID:26758086

Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem. 2016;77:1-75. PMID:27717414

Freeley S, Kemper C, Le Friec G. The "ins and outs" of complement-driven immune responses. Immunol Rev. 2016;274:16-32. PMID:27782335

Garcia BL, Zwarthoff SA, Rooijakkers SH, Geisbrecht BV. Novel Evasion Mechanisms of the Classical Complement Pathway. J Immunol. 2016;197(6):2051-60. PMID:27591336

Garred P, Genster N, Pilely K et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016;274(1):74-97. PMID:27782323

Ghebrehiwet B, Kaplan AP, Joseph K, Peerschke EI. The complement and contact activation systems: partnership in pathogenesis beyond angioedema. Immunol Rev. 2016;274:281-289. PMID:27782339

Hajishengallis G, Lambris JD. More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev. 2016;274:233-244. PMID:27782328

Hakobyan S, Luppe S, Evans DR, Harding K, Loveless S et al. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
Mult Scler. 2016. pii: 1352458516669002. [Epub ahead of print]. PMID:27613120

Hakobyan S, Harding K, Aiyaz M et al. Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. J Alzheimers Dis. 2016;54(2):707-16. PMID:27567854

Hansen SW, Ohtani K, Roy N, Wakamiya N et al. The collectins CL-L1, CL-K1 and CL-P1, and their roles in complement and innate immunity. Immunobiology. 2016;221:1058-67. PMID:27377710

He Y, Xu B, Song D, Yu F Chen Q, Zhao M. Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia
Am J Reprod Immunol. 2016;76:205-11. PMID:27461873

Holers VM, Tomlinson S, Kulik L. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016;28:260-7. PMID:27282113

Horváth Z, Csuka D, Vargova K et al. Alternative complement pathway activation during invasive coronary procedures in acute myocardial infarction and stable angina pectoris. Clin Chim Acta. 2016;463:138-144. PMID:27794429

Hourcade DE, Akk AM, Mitchell LM, Zhou HF, Hauhart R, Pham CT. Anti-complement activity of the Ixodes scapularis salivary protein Salp20. Mol Immunol. 2016;69:62-9. PMID:26675068

Huber-Lang M, Gebhard F, Schmidt CQ, Palmer A, Denk S, Wiegner R. Complement therapeutic strategies in trauma, hemorrhagic shock and systemic inflammation - closing Pandora's box? Semin Immunol. 2016;28:278-84. PMID:27157701

Hyvärinen S. REGULATION OF COMPLEMENT ACTIVATION ON SURFACES: Towards better understanding of atypical hemolytic uremic syndrome. PhD Thesis 2016, Research Programs Unit, Immunobiology Faculty of Medicine, University of Helsinki, Finland

Hyvärinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood. 2016;127:2701-10. PMID:27006390

Jani PK, Schwaner E, Kajdácsi E et al. Complement MASP-1 enhances adhesion between endothelial cells and neutrophils by up-regulating E-selectin expression. Mol Immunol. 2016;75:38-47. PMID:27219453

Jordan SC, Choi J, Kahwaji J, Vo A. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients. Transplant Proc. 2016;48:806-8. PMID:27234741

Jore MM, Johnson S, Sheppard D et al. Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol. 2016;23:378-86. PMID:27018802

Kawa S. The Immunobiology of Immunoglobulin G4 and Complement Activation Pathways in IgG4-Related Disease. Curr Top Microbiol Immunol. 2016. [Epub ahead of print]

Keizer MP, Kamp AM, Aarts C et al. The High Prevalence of Functional Complement Defects Induced by Chemotherapy. Front Immunol. 2016;7:420. PMID:27799929

Khan MA, Hsu JL, Assiri AM, Broering DC. Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective. Clin Exp Immunol. 2016 ;183:175-86. PMID:26404106

Kim C, Smith KE, Castillejos A, Diaz-Aguilar D, Saint-Geniez M, Connor KM. The alternative complement pathway aids in vascular regression during the early stages of a murine model of proliferative retinopathy. FASEB J. 2016;30:1300-5. PMID:26631482

Kleinman ME, Ambati J. Complement Activation and Inhibition in Retinal Diseases. Dev Ophthalmol. 2016;55:46-56. PMID:26501209

Kozarcanin H, Lood C, Munthe-Fog L et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost. 2016;14:531-45. PMID:26614707

Kraiczy P. Hide and Seek: How Lyme Disease Spirochetes Overcome Complement Attack.
Front Immunol. 2016;7:385. eCollection 2016. PMID:27725820

Lines SW, Richardson VR, Thomas B, Dunn EJ, Wright MJ, Carter AM. Complement and Cardiovascular Disease--The Missing Link in Haemodialysis Patients. Nephron. 2016;132:5-14. PMID:26695077

Lintner KE, Wu YL, Yang Y et al. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol. 2016 15;7:36. PMID:26913032

Magro-Checa C, Schaarenburg RA, Beaart HJ, Huizinga TW, Steup-Beekman GM, Trouw LA. Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus. 2016;25:878-88. PMID:27252265

Maibaum J, Liao SM, Vulpetti A et al. Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol. 2016;12:1105-1110. PMID:27775713

Martin M, Blom AM. Complement in removal of the dead - balancing inflammation. Immunol Rev. 2016;274:218-232. PMID:27782329

Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology. 2016;221:1046-57. PMID:27353192

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group. The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth. J Neurovirol. 2016;22:823-830. PMID:27273074

Meri S. Self-nonself discrimination by the complement system. FEBS Lett. 2016;590:2418-34. PMID:27393384

Mohan RR, Cabrera AP, Harrison RE et al. Peptide redesign for inhibition of the complement system: Targeting age-related macular degeneration. Mol Vis. 2016;22:1280-1290. PMID:27829783

Montero RM, Sacks SH, Smith RA. Complement-here, there and everywhere, but what about the transplanted organ? Semin Immunol. 2016;28:250-9. PMID:27179705

Morgan BP, Walters D, Serna M, Bubeck D. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunol Rev. 2016;274:141-151. PMID:27782334

Noone DG, Riedl M, Pluthero FG et al. Von Willebrand factor regulates complement on endothelial cells. Kidney Int. 2016;90:123-34. PMID:27236750

Okrój M, Johansson M, Saxne T, Blom AM, Hesselstrand R. Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther. 2016 18;18:267.

Pagowska-Klimek I, Swierzko AS, Michalski M, Glowacka E et al. Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery. Clin Exp Immunol. 2016;184:257-63. PMID:26703090

Paun CC, Lechanteur YT, Groenewoud JM et al. A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo. Sci Rep. 2016;6:26568. PMID:27241480

Prieto-Moure B, Lloris-Carsí JM, Barrios-Pitarque C et al. Pharmacology of Ischemia-Reperfusion. Translational Research Considerations. J Invest Surg. 2016;29:234-49. PMID:27216877

Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology. 2016 ;221:1247-58. PMID:27475991
Master Sankar Raj V, Gordillo R, Chand DH. Overview of C3 Glomerulopathy. Front Pediatr. 2016;4:45. PMID:27200326

Quadros AU, Cunha TM. C5a and pain development: An old molecule, a new target
Pharmacol Res. 2016;112:58-67. PMID:26855316

Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. PMID:27211870

Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev. 2016;274:33-58. PMID:27782325

Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol. 2016;28:208-22. PMID:27321574

Riddell A, Goodship T, Bingham C. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab?.Clin Nephrol. 2016;86:200-2. PMID:27616760

Rosbjerg A, Genster N, Pilely K, Skjoedt MO, Stahl GL, Garred P. Complementary Roles of the Classical and Lectin Complement Pathways in the Defense against Aspergillus fumigatus. Front Immunol. 2016;7:473. eCollection 2016. PMID:27857715

Rosenthal J. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016;7:181-6. PMID:27621680

Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev. 2016;274:307-329.

Schatz-Jakobsen JA, Pedersen DV, Andersen GR. Structural insight into proteolytic activation and regulation of the complement system. Immunol Rev. 2016;274:59-73. PMID:27782336

Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators.
Immunol Rev. 2016;274:152-171. PMID:27782321

Shaw PX, Stiles T, Douglas C et al. Oxidative stress, innate immunity, and age-related macular degeneration. AIMS Mol Sci. 2016;3:196-221. PMID:27239555

Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J. 2016;14(Suppl 1):19. PMID:27766045

Silva NC, Vale VF, Franco PF et al. Saliva of Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) inhibits classical and alternative complement pathways. Parasit Vectors. 2016;9:445. PMID:27515662

Sim RB, Schwaeble W, Fujita T. Complement research in the 18th-21st centuries: Progress comes with new technology. Immunobiology. 2016;221:1037-45. PMID:27371361

Smedbråten J, Mjøen G, Hartmann A et al. Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients. BMC Nephrol. 2016;17(1):148.

Sjölander J, Byman E, Kulak K et al. C4b-binding Protein Protects ?-Cells from Islet Amyloid Polypeptide-induced Cytotoxicity. J Biol Chem. 2016;291:21644-21655. PMID:27566545

Stasi?oj? G, Österborg A, Blom AM, Okrój M. New perspectives on complement mediated immunotherapy. Cancer Treat Rev. 2016;45:68-75. PMID:26994325

Taylor RP, Lindorfer MA. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol. 2016;28:309-16. PMID:27009480

Thurman JM, Nemenoff RA. Never make assumptions: the complicated role of complement in urinary tract infections. Kidney Int. 2016;90:469-71.

Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016;90:746-52. PMID:27325183

Triggianese P, Perricone C, Chimenti MS, De Carolis C, Perricone R. Innate Immune System at the Maternal-Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes. Am J Reprod Immunol. 2016;76:245-57. PMID:27108670

van Lookeren Campagne M, Strauss EC, Yaspan BL. Age-related macular degeneration: Complement in action. Immunobiology. 2016;221:733-9. PMID:26742632

Verschoor A, Karsten CM, Broadley SP, Laumonnier Y, Köhl J. Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments. Immunol Rev. 2016;274:112-126. PMID:27782330

Vlaicu SI, Tatomir A, Boodhoo D1, Vesa S, Mircea PA, Rus H. The role of complement system in adipose tissue-related inflammation. Immunol Res. 2016;64:653-64. PMID:26754764

Vlaicu SI, Tatomir A, Rus V et al. The role of complement activation in atherogenesis: the first 40 years. Immunol Res. 2016;64:1-13. PMID:26091721

Wang L, Cano M, Datta S et al. Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation.
J Pathol. 2016;240:495-506. PMID:27659908

Ward PA. In Sepsis, Complement Is Alive and Well. Crit Care Med. 2016;44:1026-7. PMID:27083023

Watkins LM, Neal JW, Loveless S et al. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. J Neuroinflammation. 2016;13:161. PMID:27333900

Westra D, Volokhina EB, van der Molen RG et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
Pediatr Nephrol. 2016 Oct 7. [Epub ahead of print]. PMID:27718086

Wiegner R, Chakraborty S, Huber-Lang M. Complement-coagulation crosstalk on cellular and artificial surfaces. Immunobiology. 2016;221:1073-9. PMID:27371975

Wu F, Zou Q, Ding X et al. Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J Neuroinflammation. 2016;13:23. PMID:26822321

Yu ZX, Qi S, Lasaro MA et al. Targeting Complement Pathways During Cold Ischemia and Reperfusion Prevents Delayed Graft Function. Am J Transplant. 2016;16:2589-97. PMID:27003920

Yuan X, Gavriilaki E, Thanassi JA et al. Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2016. pii: haematol.2016.153312. [Epub ahead of print]. PMID 27810992

Zewde N, Gorham RD Jr, Dorado A, Morikis D. Quantitative Modeling of the Alternative Pathway of the Complement System. PLoS One. 2016;11(3):e0152337. PMID:27031863

Zhang X, Hu Y, Shen J et al. Low levels of ficolin-3 are associated with diabetic peripheral neuropathy. Acta Diabetol. 2016;53(2):295-302. PMID:26116288



Back to the top

Gatault P, Brachet G, Ternant D et al. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs. 2015;7:1205-11. PMID:26337866

Ingels H, Schejbel L, Lundstedt AC et al. Immunodeficiency among children with recurrent invasive pneumococcal disease. Pediatr Infect Dis J. 2015;34:644-51. PMID:25831419

Peffault de Latour R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015;125:775-83.

Bajic,G et al. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO Journal 2015;34:2735–57,

Sfyroera G, et al. Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. J Immunol. 2015; 194:3305-16.

Frémeaux-Bacchi V, Legendre C M. The emerging role of complement inhibitors in transplantation. Kidney Int 2015;88:967-73

Mathern DR, Heeger PS. Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol 2015;10:1636-50.

Risitano A M. Dissecting complement blockade for clinic use. BLOOD 2015;125:742-4.

Wang J, et al. Complement Activity is Altered in Obstructive Sleep Apnea. Am J Respir Crit Care Med 2015;191:A2146.

Haapasalo K, et al. Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles. J Biol Chem. 2015;290:28977-87.

Berg, A et al. Complement Activation Correlates with Disease Severity and Contributes to Cytokine Responses in Plasmodium falciparum Malaria. J Infect Dis 2015; 212:1835-40.

Blom A et al. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol 2015; 66:164-70.

Egge, K. H., et al.The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin Exp Immuno 2015;181:457–67.

Hein, E., et al. Heparin-coated cardiopulmonary bypass circuits selectively deplete the pattern recognition molecule ficolin-2 of the lectin complement pathway in vivo. Clin Exp Immunol 2015;179:294–9.

Hovland A et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis 2015; 241: 480-94.

Lappegård K T A et al. Terapeutisk komplementhemming – fra eksperimentell til klinisk medisin. Therapeutic complement inhibition – from experimental to clinical medicine Tidsskr Nor Legeforen 2015;135:1745?–?9.

Smedbraten, Y V et al. High Ficolin-3 Level at the Time of Transplantation Is an Independent Risk Factor for Graft Loss in Kidney Transplant Recipients. Transplantation 2015;99:791-6.

Volokhina E B et al. Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo BLOOD 2015;126:278-9.

Volokhina E B et al.Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015;160:237–43.

Merle NS, et al. Complement system part II: role in immunity. Front. Immunol 2015; 6:257.

Salmon JEet al.Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10).

Brandstetter C et al. Complement component C5a primes retinal pigment epithelial cells for inflammasome activation by lipofuscin-mediated photooxidative damage. Journal of Biological Chemistry 2015; 290: 31189-98.

Li L, et al. Review on complement analysis method and the roles of glycosaminoglycans in the complement system. Carbohydr Polym 2015;134:590-7.

Melis JP et al. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.Mol Immunol. 2015;67:117-30.



Back to the top

Cataland S R et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014;123:3733-38

Csuka D et al. Activation of the ficolin-lectin pathway during attacks of hereditary angioedema. J Allergy Clin Immunol. 2014 Jul 16. [Epub ahead of print]

Cugno M et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014; 12:1440-8

Grumach A S, Kirschfink M.  Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Molecular Immunology 2014; 61: 110–117

Grumach A S et al. Complement profile in neonates of different gestational ages. Scand J Immunol. 2014;79:276-81

Koscielska-Kasprzak K et al. The Complement Cascade and Renal Disease. Arch. Immunol. Ther. Exp. 2014; 62:47–57

Ma R et al. The Alternative Pathway of Complement Activation May Be Involved in the Renal Damage of Human Anti-Glomerular Basement Membrane Disease. PLOS One 2014; 9: e91250; Open access

Noris M et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014;124:1715-26

Zanier ER et al. Ficolin-3-mediated lectin complement pathway activation in patients with subarachnoid hemorrhage. Neurology. 2014;82:126-34

Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost. 2014;12:1437-9



Back to the top

Barthel D et al. Plasminogen Is a Complement Inhibitor. JBC, 2012; 287:18831-18842

Brunner J et al. Analysis of the classical, alternative, and mannose binding lectin pathway of the complement system in the pathogenesis of oligoarticular juvenile idiopathic arthritis. Rheumatol Int (2012) 32:1815–1818

Cazander G et al. Maggot excretions affect the human complement system. Wound Repair Regen. 2012; 20: 879-86 (ABSTRACT)

DeAngelis RA et al. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology. 2012 ;217:1097-105

Idorn T et al. Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives; a case report. BMC Nephrology 2012; 13:64

Inoshita H et al. An analysis of functional activity via the three complement pathways during hemodialysis sessions: a new insight into the association between the lectin pathway and C5 activation. Clin Kidney J (2012) 5: 401–404

Li Y et al. Label-free quantitative proteomic analysis reveals dysfunction of complement pathway in peripheral blood of schizophrenia patients: evidence for the immune hypothesis of schizophrenia (ABSTRACT). Mol. BioSyst., 2012,8, 2664-2671

Mika A et al. Complement Inhibitors from Scabies Mites Promote Streptococcal Growth – A Novel Mechanism in Infected Epidermis? PLoS Negl Trop Dis 6(7): e1563

Nilsson B et al. Complement Diagnostics: Concepts, Indications, and Practical Guidelines. Clinical and Developmental Immunology, Volume 2012, Article ID 962702, 11 pages

Prior N et al. Development of a disease-specific quality oflife questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health and Quality of Life Outcomes 2012, 10:82

Prohászka Z et al. The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. British J Haematology, 2012, 158, 415–429

Sethi S et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney International (2012) 82, 465–473

Tudoran R & Kirschfink M. Modern complement analysis: indications, methods and outlook. J Lab Med 2012;36:XX. doi10.1515/


Back to the top

Barratt-Due A et al. Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. J Immunol, 2011;187: 000–000

Bergseth G et al. Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person. Ann Thorac Surg. 2011; 91: 527–533.

Ehrnthaller C et al. New insights of an old defense system: Structure, function, and clinical relevance of the complement system. Mol Med 2011;17: 317-329.

Fridkis-Hareli M et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases. Blood. 2011;118:4705-4713

Grimnes G et al. Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient—a case report. APMIS 2011

Harboe M et al. Advances in assay of complement function and activation. Adv Drug Deliv Rev 2011;xx:xx. 10.1016/j.addr.2011.05.010

Ilyas R et al. High Glucose Disrupts Oligosaccharide Recognition Function Via Competitive Inhibition: A Potential Mechanism for Immune Dysregulation in Diabetes Mellitus. Immunobiology 2011; 216: 126–131

Martel C et al. Requirements for Membrane Attack Complex Formation and Anaphylatoxins Binding to Collagen-Activated Platelets. PLoS One 2011; 6: e18812

Oberbach A et al. Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J. Proteome Res. 2011, 10, 4769–4788

Reusz G.S. et al. Diagnosis and Classification of Hemolytic Uremic Syndrome: The Hungarian Experience. Transplantation Proceedings, 43, 1247–1249 (2011)

Senbagavalli P et al. Heightened Measures of Immune Complex and Complement Function and Immune Complex–Mediated Granulocyte Activation in Human Lymphatic Filariasis. Am. J. Trop. Med. Hyg. 2011; 85: 89–96

Sethi S et al. Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement. Clin J Am Soc Nephrol 6: 1009–1017, 2011

van Werkhoven M.B. et al.Increased renal C5a receptor expression and systemic complement activation in brain dead donors. MOL IMMUNOL 2011; 48(14):1729-1729


Back to the top

Castellano G, et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. The American Journal of Pathology, Vol. 176, No. 4, April 2010

Hamad I et al. Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere_Serum Interface: Implications for Stealth Nanoparticle Engineering. acsnano 2010; 4: 6629–6638

Inoshita H et al. Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis. BMC Nephrology 2010; 11:34

Kadam A P et al. Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. The Journal of Immunology, 2010, 184: 000–000

Kocsis A et al. Selective Inhibition of the Lectin Pathway of Complement with Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway Activation. J Immunol 2010; 185:4169-4178

Maga T K et al. A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. Nephrol Dial Transplant (2010) 1 of 3, doi: 10.1093/ndt/gfq658

Orth D et al. EspP, a Serine Protease of Enterohemorrhagic Escherichia coli, Impairs Complement Activation by Cleaving Complement Factors C3/C3b and C5. INFECTION AND IMMUNITY 2010; 78: 4294–4301

Zimmerhackl L B et al. Prophylactic Eculizumab after Renal Transplantation in Atypical Hemolytic–Uremic Syndrome. The New England Journal of Medicine 362;18, May 6, 2010


Back to the top

Botto et al. Complement in human disease: Lessons from complement deficiencies. Mol Immunol 2009;XX: XX. doi:10.1016/j.molimm.2009.04.029.

Ceribelli A et al. Complement Cascade in Systemic Lupus Erythematosus Analyses of the Three Activation Pathways. Ann. N.Y. Acad. Sci. 2009; 1173: 427–434

Lappegård K T et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature. PNAS 2009; 106: 15861–15866

Nyakoe N K et al. Consumption in children with Plasmodium falciparum Malaria. Malaria Journal 2009, 8:7 doi:10.1186/1475-2875-8-7

Salvesen B, Mollnes TE. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Molecular Immunology 2009; 46: 1620-1625


Back to the top

Burman J D et al. Interaction of Human Complement with Sbi, a Staphylococcal Immunoglobulin-binding Protein - INDICATIONS OF A NOVEL MECHANISM OF COMPLEMENT EVASION BY STAPHYLOCOCCUS AUREUS. JBC 2008; 283: 17579–17593

Hamad I et al. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol 2008; 45: 3797–3803

Kimura Y et al. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 2008; 111: 732-740

Kuo C-F et al. Degradation of Complement 3 by Streptococcal Pyrogenic Exotoxin B Inhibits Complement Activation and Neutrophil Opsonophagocytosis. Infection and Immunity 2008; 76: 1163–1169

Upadhyay A et al. Structure-Function Analysis of the C3 Binding Region of Staphylococcus aureus Immune Subversion Protein Sbi. JBC 2008; 283: 22113–22120

Varga L et al. Depressed activation of the lectin pathway of complement in hereditary angioedema. Clin Exp Immunol 2008; 153: 68–74


Back to the top

Manuel  O et al. Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. Transplant Infectious Disease 2007; 9: 214-218

Mollnes TE et al. Complement analysis in the 21st century. Mol Immunol 2007;44: 3838-3849.

Waage Nielsen E et al. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol 2007; 44: 1819–1826



Back to the top

Fevang B et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol 2005; 142:576–584

Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005;296: 187-198.


Svar Life Science AB (formerly Euro Diagnostica)

Mailing address:
P.O. Box 50117
SE-202 11 Malmö

Visiting address:
Lundavägen 151
212 24 Malmö

VAT No. SE556564064501


Phone: +46 40 53 76 00 

Please mail your order to:

Please visit our contact section for information about local offices around the world

Shortcuts and important links

Share on Google+ Share on LinkedIn Share on Twitter Share on Facebook

© 2000-2018 Svar Life Science AB
All rights reserved.